The Food and Drug Administration (FDA) has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients aged 12 years and older who are ...

Johnson & Johnson's (J&J) human neonatal Fc receptor (FcRn)-blocking monoclonal antibody Imaavy (nipocalimab-aahu) has ...

For details, see the “Before receiving Ultomiris” section. With myasthenia gravis, dysfunctional muscle ... begins with a loading dose. Two weeks after the loading dose, you’ll continue ...

While Johnson & Johnson isn't the first to secure FDA approval for an FcRn-blocking antibody in myasthenia gravis, the New ...

May 2, 2025 -- The FDA has approved a new treatment for generalized myasthenia gravis (gMG ... or redness of skin during or a few days after Imaavy infusion. Before or during treatment, patients ...

Changes in intravenous or subcutaneous immunoglobulin usage before and after efgartigimod initiation in patients with myasthenia gravis. Poster presented at: AMCP 2025; March 31-April 3 ...

Johnson & Johnson ’s anti-FcRn antibody nipocalimab has been approved by the FDA to treat generalized myasthenia gravis. The ...

The UK regulatory authority has cleared the path for some patients with generalised myasthenia gravis (gMG ... Both decisions are expected before the end of the year. Meanwhile, Argenx is also ...

Nicholas J. Silvestri, MD, describes how this year’s AAN meeting highlighted significant advances in myasthenia gravis, including improved diagnostics through cell-based assays that enhance ...

in the treatment of adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody positive and adults with chronic inflammatory demyelinating polyneuropathy (CIDP).

Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.